SCHEMBL15031983

SCHEMBL15031983

Cc1ccccc1C(=O)c1ccc(Br)cc1C(=O)O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 1/20 0.53
CYP2C9 P11712 1/20 0.53
KMT2A Q03164 1/20 0.53
SORT1 Q99523 5/20 0.52
AKR1C3 P42330 1/20 0.51
ALDH1A1 P00352 2/20 0.51
GSTA1 P08263 1/20 0.50
MAPK13 O15264 2/20 0.49
MAPK12 P53778 2/20 0.49
MAPK11 Q15759 2/20 0.49
MAPK14 Q16539 2/20 0.49
CDC25A P30304 1/20 0.49
CDC25B P30305 1/20 0.49
HSD17B10 Q99714 1/20 0.49
MYC P01106 1/20 0.46
NR4A1 P22736 1/20 0.46
KDM4E B2RXH2 1/20 0.46
GLA P06280 1/20 0.46
NPC1 O15118 1/20 0.45
RAB9A P51151 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL357669 0.82 CYP3A4 (0.72) CYP3A4CYP2C9KMT2AAKR1C3ALDH1A1
SCHEMBL31696155 0.82 MAPT (0.63) CYP3A4CYP2C9GSTA1MAPK13MAPK12
SCHEMBL8785629 0.81 ALDH1A1 (0.64) CYP3A4CYP2C9KMT2AAKR1C3ALDH1A1
SCHEMBL4676503 0.80 CDC25B (0.55) KMT2AAKR1C3ALDH1A1GSTA1CDC25B
SCHEMBL4704774 0.80 MAPT (0.69) CYP2C9SORT1AKR1C3ALDH1A1CDC25A
SCHEMBL17332 0.79 KDM4E (0.59) CYP2C9KMT2ASORT1MYCNR4A1
SCHEMBL29571243 0.79 KDM4E (0.59) CYP2C9KMT2ASORT1MYCNR4A1
SCHEMBL10669335 0.78 CYP3A4 (0.59) CYP3A4CYP2C9KMT2AALDH1A1MAPK13
SCHEMBL10731388 0.78 KMT2A (0.50) CYP3A4CYP2C9KMT2AAKR1C3ALDH1A1
SCHEMBL5153378 0.77 CDC25B (0.48) CYP2C9SORT1ALDH1A1CDC25BHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9012443-B2 Bicyclic aryl and heteroaryl sodium channel inhibitors AMGEN INC. (US) 2015-04-21 US disclosed
US-20130150339-A1 Bicyclic Aryl and Heteroaryl Sodium Channel Inhibitors AMGEN INC. (US) 2013-06-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130150339-A1 Bicyclic Aryl and Heteroaryl Sodium Channel Inhibitors SCN1A, SCN1B, CACNA1B CYP3A4 539/4885CYP2C9 218/4885KMT2A 1920/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.